Top Clinical Trials

Deepak L. Bhatt, MD, MPH, FACC
Senior Associate Editor, Clinical Trials and News, ACC.org

By views, here are the top 10 trials on ACC.org for 2019, in alphabetical order. Some were first presented in 2018 or even earlier, but trial updates were presented in 2019 and highly viewed. This certainly attests to the ongoing scientific contributions that can come from randomized trials beyond the primary analysis. ISCHEMIA topped the list by an enormous margin, even though it was on the list for only a month, with the remainder of the listed trials clustered relatively close together. It is amazing to see diabetes trials represented so prominently – a sign of the evolution of cardiology to both study and treat all cardiovascular risk factors.

— Deepak L. Bhatt, MD, MPH, FACC

• AUGUSTUS: Antithrombotic Therapy After Acute Coronary Syndrome or PCI in Atrial Fibrillation
• DAPA-HF: Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction
• DECLARE-TIMI 58: Dapagliflozin Effect on Cardiovascular Events–Thrombolysis in Myocardial Infarction 58
• EMPA-REG OUTCOME: Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients
• EVAPORATE: Effect of Icosapent Ethyl on Progression of Coronary Atherosclerosis in Patients With Elevated Triglycerides on Statin Therapy
• ISAR-REACT 5: Intracoronary Stenting and Antithrombotic Regimen 5
• ISCHEMIA: International Study of Comparative Health Effectiveness With Medical and Invasive Approaches
• REDUCE-IT: Reduction of Cardiovascular Events With Icosapent Ethyl–Intervention Trial
• STOP-DAPT 2: Short and Optimal Duration of Dual Antiplatelet Therapy After Everolimus-Eluting Cobalt-Chromium Stent-2
• VITAL: Vitamin D and Omega-3 Trial

Top Journal Scans

Kim A. Eagle, MD, MACC
Editor-in-Chief, ACC.org

The most popular ACC journal scans for 2019 were in topic areas where there has been rapid progress in diagnosis and/or management. These include new insights into the diagnosis of pulmonary embolism, whether we should use aspirin for primary prevention, evolution in hypertension therapies and dramatic shifts in our use of catheter-based valve therapies. At ACC.org, our goal is to bring our learners the most important information for the practice of cardiovascular care in formats that are easily accessed and digested. Between journal scans, weekly podcasts, news summaries, FDA alerts and clinical trial summaries we hope to cover the material that is important to you as the practice of cardiovascular care evolves.

— Kim A. Eagle, MD, MACC

• Diagnosis of Pulmonary Embolism
• Aspirin for Primary Prevention of CV Events
• Oral Antihypertensives for Management of Severe Hypertension in Pregnancy
• Direct Oral Anticoagulants for Mitral Stenosis
• Metformin Use and CV Outcomes Among Diabetes Patients
• Bicuspid vs. Tricuspid TAVR Outcomes
• Effect of Coronary CT Angiography and Outcomes
• Anticoagulation After Bioprosthetic Valve Replacement or TAVR
• Aspirin Use for Primary Prevention of CV and Bleeding Events
• Sleep Duration and Myocardial Infarction

Keywords: Acute Coronary Syndrome, Anticoagulants, Arrhythmias, Cardiac, Cardiac Surgical Procedures, Metabolic Syndrome, Angina, Stable, Heart Defects, Congenital, Dyslipidemias, Geriatrics, Heart Failure, Angiography, Diagnostic Imaging, Pericarditis, Secondary Prevention, Hypertension, Pulmonary, Sleep Apnea Syndromes, Sports, Aneurysm

< Back to Listings